0000899243-22-032687.txt : 20221004 0000899243-22-032687.hdr.sgml : 20221004 20221004170023 ACCESSION NUMBER: 0000899243-22-032687 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221001 FILED AS OF DATE: 20221004 DATE AS OF CHANGE: 20221004 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Habibizad Nazila CENTRAL INDEX KEY: 0001913961 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 221292735 MAIL ADDRESS: STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC. STREET 2: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-10-01 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001913961 Habibizad Nazila C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Common Stock 2022-09-29 5 G 0 E 3500 0.00 D 38123 D Common Stock 2022-10-01 4 M 0 1375 A 39498 D Common Stock 2022-10-01 4 M 0 182 A 39680 D Restricted Stock Units 2022-10-01 4 M 0 1375 0.00 D Common Stock 1375 2750 D Restricted Stock Units 2022-10-01 4 M 0 182 0.00 D Common Stock 182 548 D Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the original grant of 11,000 RSUs vest in eight semi-annual installments after October 1, 2019 through October 1, 2023, subject to the Reporting Person's continuous service with the Issuer through each vesting date, and have no expiration date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the original grant of 1,461 RSUs vest in eight semi-annual installments after April 1, 2020 through April 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each vesting date, and have no expiration date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Executive Vice President, Operations /s/ Miguel Carrillo, Attorney-in-Fact 2022-10-04